REWRITING THE RULES OF DRUG CREATION Trademark
Trademark Overview
On Friday, October 7, 2022, a trademark application was filed for REWRITING THE RULES OF DRUG CREATION with the United States Patent and Trademark Office. The USPTO has given the REWRITING THE RULES OF DRUG CREATION trademark a serial number of 97623507. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, May 21, 2024. This trademark is owned by Cellarity, Inc.. The REWRITING THE RULES OF DRUG CREATION trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders
Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases
Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research ...
General Information
| Serial Number | 97623507 |
| Word Mark | REWRITING THE RULES OF DRUG CREATION |
| Filing Date | Friday, October 7, 2022 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, May 21, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 26, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical, therapeutic and biopharmaceutical preparations and agents for the treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders |
| Goods and Services | Medical diagnostic and screening services, namely, conducting diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases |
| Goods and Services | Research and development of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; research and development of technology in the field of pharmaceutical, therapeutic and biopharmaceutical preparations and agents; drug development and discovery; scientific research in the field of drug discovery and development; biomedical research services; pharmaceutical drug development services, namely, preclinical development of therapeutic products; bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; providing temporary use of non-downloadable computer software involving the use of artificial intelligence technology for molecular design; scientific diagnostic and screening services, namely, conducting scientific diagnostic testing and evaluation of molecules developed through artificial intelligence means for the combating of diseases; scientific research, namely, research and analysis services in the fields of artificial intelligence and machine learning analytics and research relating to drug development; providing on-line non-downloadable software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for data analysis in the fields of healthcare, biomedical and genomic research; providing on-line non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, October 31, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 1, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 1, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Cellarity, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Somerville, MA 02143 |
| Party Name | Cellarity, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Somerville, MA 02143 |
Trademark Events
| Event Date | Event Description |
| Monday, October 31, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, April 6, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Friday, July 21, 2023 | ASSIGNED TO EXAMINER |
| Friday, August 4, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, August 4, 2023 | NON-FINAL ACTION E-MAILED |
| Friday, August 4, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, November 3, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, November 3, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, January 31, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, January 31, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 1, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, February 20, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, February 20, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, February 20, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, February 20, 2024 | ASSIGNED TO LIE |
| Tuesday, February 20, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, February 20, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 6, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, March 6, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 26, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 26, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 21, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, November 14, 2024 | SOU TEAS EXTENSION RECEIVED |
